Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11015277 | 0.95 | SIRT6 (0.34) | SIRT6SIRT1CPB2FOLH1PAOX | |
| SCHEMBL7224725 | 0.84 | ANPEP (0.44) | SIRT6SIRT1CPB2FOLH1GSR | |
| SCHEMBL7224727 | 0.84 | ANPEP (0.44) | SIRT6SIRT1CPB2FOLH1GSR | |
| SCHEMBL4902767 | 0.82 | SIRT1 (0.40) | SIRT6SIRT1CPB2FOLH1GSR | |
| SCHEMBL5271108 | 0.81 | CPB2 (0.54) | SIRT6SIRT1CPB2FOLH1GSR | |
| SCHEMBL5271116 | 0.81 | CPB2 (0.54) | SIRT6SIRT1CPB2FOLH1GSR | |
| SCHEMBL6151760 | 0.80 | FOLH1 (0.41) | SIRT6SIRT1CPB2FOLH1GSR | |
| SCHEMBL24642434 | 0.80 | SIRT6 (0.44) | SIRT6SIRT1CPB2FOLH1GSR | |
| SCHEMBL4727759 | 0.79 | SIRT6 (0.46) | SIRT6SIRT1FOLH1PAOXTLR2 | |
| SCHEMBL4727757 | 0.79 | SIRT6 (0.46) | SIRT6SIRT1FOLH1PAOXTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940791-B2 | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2789341-A2 | O-acetylated amino acids as anti-platelet agents and nutritional supplements | Chandran, V. Ravi (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140200256-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| US-20110312890-A1 | ACETYLATED AMINO ACIDS AS ANTI-PLATELET AGENTS, NUTRITIONAL AND VITAMIN SUPPLEMENTS | SIGNATURE R&D HOLDINGS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110275713-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2011-11-10 | — | — | US | disclosed |
| US-8003683-B2 | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070112060-A1 | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements | SIGNATURE R&D HOLDINGS, LLC | 2007-05-17 | — | — | US | disclosed |
| EP-1021189-A1 | METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS AND VASCULAR INJURY BY PREVENTION OF VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | Keystone Biomedical, Inc. (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0996450-A2 | METHOD FOR THE TREATMENT OF CANCER WITH EXOCHELINS OF MYCOBACTERIUM TUBERCULOSIS | Keystone Biomedical, Inc. (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1998058635-A2 | METHOD FOR THE TREATMENT OF CANCER WITH EXOCHELINS OF MYCOBACTERIUM TUBERCULOSIS | KEYSTONE BIOMEDICAL INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| WO-1998034619-A1 | METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS AND VASCULAR INJURY BY PREVENTION OF VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | KEYSTONE BIOMEDICAL, INC. (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200256-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | PLTP, GP6, PDGFA | SIRT6 175/4885SIRT1 128/4885CPB2 1336/4885 |
| US-20110312890-A1 | ACETYLATED AMINO ACIDS AS ANTI-PLATELET AGENTS, NUTRITIONAL AND VITAMIN SUPPLEMENTS | PLTP, GP6, PDGFA | SIRT6 175/4885SIRT1 128/4885CPB2 1336/4885 |
| US-20070112060-A1 | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements | PLTP, GP6, PDGFA | SIRT6 175/4885SIRT1 128/4885CPB2 1336/4885 |
| US-20110275713-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | PLTP, GP6, PDGFA | SIRT6 175/4885SIRT1 128/4885CPB2 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.